ADVANCE STAGE OF HODGKIN LYMPHOMA SHOWS HIGH DENSITY OF PLASMA CELLS BUT LOW ANGIOGENESIS

Krisna Murti; Neti Neti; Iche Andriyani Liberty

doi:10.32539/mks.v55i1.21035

ADVANCE STAGE OF HODGKIN LYMPHOMA SHOWS HIGH DENSITY OF PLASMA CELLS BUT LOW ANGIOGENESIS

Krisna Murti, Neti Neti, Iche Andriyani Liberty

Abstract

Background

Tumor microenvironmental of classical Hodgkin lymphoma (cHL) containing plasma cells and angiogenesis, however their exact roles remained indeterminate. Plasma cells are important prognostic factors of various malignancies. Angiogenesis can be assessed by evaluating of micro vessel density (MVD). Higher MVD is associated with a poor prognosis in various type of malignancies. The objectives of this study were to investigate the density of plasma cells and MVD in the microenvironment of cHL and to determine the association of both components with the stage of cHL.

Materials and methods

The selected 37 paraffin blocks of cHL cases were sectioned. The clinical staging was performed using modification of Ann Arbor staging system. To assess the density of plasma and endothelial cells, anti-CD138 and anti-CD34 antibodies were employed by immunohistochemistry. The association of plasma cells’densities and MVD with cHL stages was measured by statistical analysis using t-test by STATA version 15 with significant consideration if p <0.05.

Results

In our cohort cHL was occurred in slightly older patients (?40 years; 53.33%), more in male (60%), and majority with nodal location (86.67%). The subtypes was dominated by lymphocyte rich (43.33%); followed by nodular sclerosing (30%) and mixed cellularity (26.67%), while lymphocyte depleted was not found. Statistical analysis revealed that higher density of plasma cells was significantly correlated to the patient higher stages (p=0.0003). While density of micro vessels is not significant correlation (p=0.5564) to the stages of cHL

Conclusion

High densities of plasma cells but not angiogenesis correlate to advance stage of Hodgkin lymphoma.

Keywords

Hodgkin lymphoma, plasma cells, angiogenesis, advance stage, CD138, CD34

Full Text:

PDF

References

Huang J, Pang WS, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol. 2022;15(1):57. http://dx.doi.org/10.1186/s13045-022-01281-9.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. http://dx.doi.org/10.3322/caac.21660.

Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018; 93: 704– 715. https://doi.org/10.1002/ajh.25071.

Opinto G, Agostinelli C, Ciavarella S, Guarini A, Maiorano E, Ingravallo G. Hodgkin Lymphoma: A Special Microenvironment. J Clin Med. 2021;10(20):4665. https://doi.org/10.3390/jcm10204665.

Menéndez V, Solórzano JL, Fernández S, Montalbán C, García JF. The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good. Cancers. 2022; 14(5):1360. https://doi.org/10.3390/cancers14051360.

Gholiha AR, Hollander P, Hedstrom G, Sundstrom C, Molin D, Smedby KE, et al. High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms. Br J Haematol. 2019;184(2):192-201. https://doi.org/10.1111/bjh.15703.

Jiang L, Li N. B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. Angiogenesis. 2020;23(4):515-529. https://doi.org/10.1007/s10456-020-09729-7.

Agnani B, Solanki R, Ansari M, Agnani S. Prognostic Significance of Microvessel Density as Assessed by anti CD34 Monoclonal Antibody in Invasive Ductal Carcinoma of Breast. Asian Pac J Cancer Biol. 2020;5(3):75-79. https://doi.org/10.31557/APJCB.2020.5.3.75-79.

den Uil SH, van den Broek E, Coupé VMH, Vellinga TT, Delis-van Diemen PM, Bril H, et al. Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study. BMC Gastroenterol. 2019;19(1):146. https://doi.org/10.1186/s12876-019-1063-4.

Martinovic Z, Kovac D, Martinovic M. Prognostic Significance of Microvessel Density Determining by Endoglin in Stage II Rectal Carcinoma: A Retrospective Analysis. Gastroenterol Res Pract. 2015;2015:504179. https://doi.org/10.1155/2015/504179.

Koh YW, Han JH, Yoon DH, Suh C, Huh J. PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma. Ann Hematol. 2017;96(11):1883-1890. https://doi.org/10.1007/s00277-017-3115-6.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. https://doi.org/10.1200/JCO.2013.54.8800.

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. https://doi.org/10.1182/blood-2016-01-643569.

Gaiolla RD, Domingues MA, Niéro-Melo L, de Oliveira DE. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med. 2011;135(4):483-9. https://doi.org/10.5858/2010-0060-OA.1.

Hanamoto H, Nakayama T, Miyazato H, Takegawa S, Hieshima K, Tatsumi Y, et al. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol. 2004;164(3):997-1006. https://doi.org/10.1016/S0002-9440(10)63187-2.

Visser L. Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?. Br J Haematol. 2019;184(2):119-120. https://doi.org/10.1111/bjh.15704.

Isaeva OI, Sharonov GV, Serebrovskaya EO, Turchaninova MA, Zaretsky AR, Shugay M, et al. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes. J Immunother Cancer. 2019;7(1):279. https://doi.org/10.1186/s40425-019-0747-1.

Filipiak J, Boi?ska J, and Ro?? D. Angiogenesis in Hodgkin’s lymphoma. Med Res J, 2017;2(3):83–88. https://doi.org/10.5603/MRJ.2017.0010.

Korkolopoulou P, Thymara I, Kavantzas N, Vassilakopoulos TP, Angelopoulou MK, Kokoris SI, et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia. 2005;19(6):894-900. https://doi.org/10.1038/sj.leu.2403690.

Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis. 2007;39(2):212-20. https://doi.org/10.1016/j.bcmd.2007.04.001.

Filipiak J, Boinska J, Zio?kowska K, Zdu?ska M, Zarychta E, Ro?? D. Assessment of endothelial progenitor cells, VEGF-A and SDF-1? in Hodgkin's lymphoma. Blood Coagul Fibrinolysis. 2021;32(4):266-272. https://doi.org/10.1097/MBC.0000000000001031.

Rueda A, Olmos D, Vicioso L, Quero C, Gallego E, Pajares-Hachero BI, et al. Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. Leuk Lymphoma. 2015;56(5):1286-94. https://doi.org/10.3109/10428194.2014.952227.

DOI: https://doi.org/10.32539/mks.v55i1.21035